budesonide + formoterol + montelukast

This is a fixed-dose combination therapy consisting of three active pharmaceutical ingredients: - **Budesonide** is an inhaled corticosteroid that reduces airway inflammation by inhibiting multiple types of inflammatory cells and decreasing the production of cytokines and other mediators involved in asthma and COPD. - **Formoterol** is a long-acting beta2-adrenergic agonist (LABA) that acts as a bronchodilator, relaxing bronchial smooth muscle to improve airflow. - **Montelukast** is an oral leukotriene receptor antagonist that blocks cysteinyl-leukotriene type 1 receptors, reducing bronchoconstriction, airway edema, and inflammation. The combination targets multiple pathways in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), aiming to provide superior control over symptoms compared to monotherapy or dual therapy. Clinical studies have shown this triple regimen can improve cough symptoms, decrease cough reflex sensitivity, alleviate eosinophilic airway inflammation in cough variant asthma (CVA), and enhance lung function in COPD[1][3]. Montelukast adds anti-leukotriene activity to the anti-inflammatory effects of budesonide/formoterol[1][3].

Brand names

SymbicortSingulair

Other names

ICS/LABA and Montelukastbudesonide/formoterol plus montelukastinhaled corticosteroid/long-acting beta agonist + montelukast